British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
Fall and winter bring an uptick in seasonal illnesses as the University community returns to campus and temperatures get cooler. The information below can help you and your community stay healthy ...
Bizcommunity on MSN2d
When it’s not flu…While the ‘official’ flu season may still be a month or two away, reports indicate a rise in respiratory illnesses like the ...
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the ...
Pharmaceutical Technology on MSN3d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback